Named Lecture:
129. Caroline B. Hall Lectureship
Friday, October 5, 2018: 10:30 AM-11:45 AM
Room: S 214-216

Learning Objectives:

At the conclusion of the session, participants will be able to:

  • describe challenges in the development of RSV vaccines
  • identify types of RSV vaccines and mAbs currently in development and target populations for each product

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, HIV clinicians, HIV specialists, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Investigators, Lab personnel, Medical students and residents, Members-in-training, Microbiologists, Nurses, Pharmacists, Public health practitioners, Researchers, Scientists, Vaccinologists

Tracks: Transplant ID, Trainee, Pediatric ID, Investigative ID, HIV-STD-TB, Global ID, Epidemiology and Infection Control, Adult ID


Moderator:  Janet Englund, MD, FIDSA, Seattle Children's Hospital

Presentations:
10:30 AM
982
Summer outbreak of severe RSV-B disease, Minnesota, 2017
Beth Thielen, MD, PhD; Erica Bye, MPH; Xiong Wang, DVM, PhD; Hannah Friedlander, MPH; Stacene Maroushek, MD, PhD; Meghan Shilts, MHS; Anna Strain, PhD; Kathryn Como-Sabetti, MPH; Patricia Ferrieri, MD, FIDSA; Ruth Lynfield, MD, FIDSA

10:45 AM
983
RSV Vaccines: Where Do We Go From Here?
Ruth A. Karron, MD, FIDSA

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-18-228-L01-P

Disclosures:

J. Englund, Medimmune: Investigator , Research support . Novavax: Investigator , Research support . Chimerix: Investigator , Research support . Gilead: Scientific Advisor , Consulting fee . Janssen: Investigator , Research support . Sanofi: Consultant , Consulting fee .

See more of: Named Lecture

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.